Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:50:53.420Z.
Calculation as of: 2026-10-06T15:50:53.420Z.
Quote observation: 2026-10-06T15:50:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bae8dd55c1776b4784265b7d6b815fecf0da21712464e51122872d0292d60ac3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$3.55B
EV/Sales Ratio
14.11x
TTM Avg
43.04x
3Y Avg
154.35x
5Y Avg
99.29x
Market Cap
$3.53B
EV/Sales Ratio
4.86x
TTM Avg
6.74x
3Y Avg
6.56x
5Y Avg
7.80x
Market Cap
$3.43B
EV/Sales Ratio
2.74x
TTM Avg
3.65x
3Y Avg
3.66x
5Y Avg
4.78x
Market Cap
$3.42B
EV/Sales Ratio
2809.83x
TTM Avg
5544.59x
3Y Avg
5544.59x
5Y Avg
2117.19x
Market Cap
$3.14B
EV/Sales Ratio
822.70x
TTM Avg
1123.66x
3Y Avg
904.58x
5Y Avg
368.85x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celcuity Inc. (CELC) | $3.55B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.55B | 14.11x | 43.04x | 154.35x | 99.29x |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | 4.86x | 6.74x | 6.56x | 7.80x |
| CareDx, Inc (CDNA)vs › | $3.45B | 6.75x | 3.21x | 2.88x | 3.18x |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.43B | 2.74x | 3.65x | 3.66x | 4.78x |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.42B | 2809.83x | 5544.59x | 5544.59x | 2117.19x |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.38B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.14B | 822.70x | 1123.66x | 904.58x | 368.85x |
| ICU Medical, Inc. (ICUI)vs › | $3.98B | 2.30x | 2.08x | 2.00x | 2.38x |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.08B | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
